Tagmokitug  (Synonyms: CHS-114; SRF-114)

Tagmokitug (CHS-114; SRF-114) is a fully human IgG1 antibody targeting CCR8. Tagmokitug selectively binds to human CCR8 (K_d = 502 pM) and mediates the death of CCR8-expressing cells via antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis. Tagmokitug selectively eliminates intratumoral regulatory T cells, induces tumor growth inhibition, remodels the tumor immune microenvironment, and promotes the differentiation of cytotoxic CD8⁺ T cell subsets. Tagmokitug can be used for the research of solid tumors^[1].

Human IgG1 lambda2

Human IgG1 lambda2, Isotype Control

Human

Tagmokitug (4 h) potently induces NK cell-mediated ADCC against Raji-huCCR8 cells, with an EC₅₀ of 2 ng/mL^[1].
Tagmokitug (3 h) potently induces macrophage-mediated antibody-dependent cellular phagocytosis (ADCP) against Raji-huCCR8 cells, with an EC₅₀ of 13.5 ng/mL^[1].
Tagmokitug (overnight treatment) selectively eliminates intratumoral regulatory T cells (Tregs) in co-culture systems of activated NK cells with dissociated tumor cells from primary renal cell carcinoma (RCC) and colorectal cancer (CRC), while preserving conventional CD4⁺ and CD8⁺ T cells, and activates NK cells and monocytes^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Tagmokitug (10 mg/kg; administered on days 6, 9, 13, 16 and 20 post tumor inoculation; 5 doses total) achieves 62.6% tumor growth inhibition in MC38 tumor-bearing huCCR8KI mice by depleting intratumoral regulatory T cells (Tregs) and remodeling the tumor immune microenvironment to expand the cytotoxic CD8⁺ T cell population^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1237  [NCBI]

P51685

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

144.12 kDa

3024486-14-1

Liquid

Colorless to light yellow

[Tagmokitug]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  IgG1-lambda

• [1]. Wang X, et al. CHS-114: an afucosylated anti-CCR8 monoclonal antibody that selectively depletes intratumoral Treg cells and induces antitumor immune responses. Mol Cancer Ther. Published online December 22, 2025.  [Content Brief]